加载中
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
常规交易时段
US$2.24
+US$0.024 · +1.08%
盘中时间采用ET。市场数据可能有所延迟。
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
日内区间
当前US$2.24
52周区间
当前US$2.24
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
45
合理估值
情绪
52
多空交织
风险
62
高风险
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
日内区间
当前US$2.24
52周区间
当前US$2.24
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 118.94万 USD | 2894万 USD | 480万 USD | — | — |
| 销货成本 | 75.9万 USD | 926.3万 USD | 369.2万 USD | — | — |
| 毛利 | 43.04万 USD | 1967.7万 USD | 110.8万 USD | — | — |
| 研究与开发 | 765.83万 USD | 914.9万 USD | 1251.9万 USD | 1762.9万 USD | 1946.6万 USD |
| 销售、一般及管理费用 | 314.07万 USD | 2854万 USD | 3123万 USD | 1152.8万 USD | 526.9万 USD |
| 营业费用 | 1079.9万 USD | 4008.5万 USD | 5080.2万 USD | 2915.7万 USD | 2477.7万 USD |
| 利息收入 | 113.29万 USD | 182.86万 USD | 200.7万 USD | 69.4万 USD | 55.9万 USD |
| 利息支出 | 129.02万 USD | 916.23万 USD | 216.9万 USD | 215.8万 USD | 98.4万 USD |
| 折旧和摊销 | 52.71万 USD | 406.5万 USD | 138.4万 USD | 65.4万 USD | 70.3万 USD |
| 营业利润 | −1036.86万 USD | −2040.8万 USD | −4969.4万 USD | −2915.7万 USD | −2477.7万 USD |
| 净利润 | −118.43万 USD | −922.1万 USD | −6061.4万 USD | −2495.1万 USD | −2705.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年1月30日 | 1:40 | — | — |
股票拆分 | 2019年7月15日 | 1:15 | — | — |
已生效 2025年1月30日
1:40
已生效 2019年7月15日
1:15
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
